BioCentury
ARTICLE | Company News

EC approves BioCryst's Alpivab for influenza

May 1, 2018 7:20 PM UTC

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat uncomplicated influenza in patients at least two years old.

The injectable formulation of a viral neuraminidase inhibitor is approved in multiple countries, including the U.S. and Japan. BioCryst declined to discuss its launch date or price...